- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03148990
Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella (BIOMR)
August 12, 2020 updated by: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
A Phase II / III, Clinical Trial to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella, Produced by Bio-Manguinhos / Fiocruz in 11-month-old Infants.
Measles and rubella are highly contagious acute viral diseases.
As per WHO, several evidences demonstrate the benefit for providing the universal access to vaccines containing measles and rubella antigens, mainly due to, respectively, mortality in children and malformations in fetuses.
This is a Phase I-III, Controlled, randomized and double blind for the evaluation double viral vaccine anti-measles and rubella (MR), which is developed and produced at Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz, in Brazil, for use in human beings.
432 eligible volunteers (11-month-old infants), will be vaccinated and monitored for local and systemic adverse events and titration of antibodies.
The study will last 11 months in total.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This is a Phase II-III, controlled, randomized and double blind for the evaluation of a double viral vaccine anti measles and rubella (MR), which is under the development at Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz, in Brazil, for use in human beings.
432 eligible volunteers (11-month-old infants), will be vaccinated and monitored for local and systemic adverse events and immunogenicity.
The study will last 11 months in total.
Study Type
Interventional
Enrollment (Actual)
432
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rio de Janeiro, Brazil, 21040900
- Secretaria Municipal de Saúde do Estado do Rio de Janeiro
-
-
Rio Grande Do Norte
-
Natal, Rio Grande Do Norte, Brazil, 59.025-050
- Centro de Estudos e Pesquisas em Moléstias Infecciosas Ltda (CPCLIN)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
11 months to 11 months (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Both sex;
- Good health (no significant medical history);
- 11 months of age on the first dose of vaccine;
- To be up-to-date with the national vaccination calendar;
- Availability for follow-up throughout the study period;
- Willing to provide name, address, telephone and other contact information in order to be contacted, whenever needed (example: in case of missing any scheduled visit, contact for confirmation of scheduling a visit, urgent safety notifications);
- Willing to strictly follow the study protocol;
- At least one legal guardian of the research participants must be able to understand and sign the informed consent form;
- Legal guardians by the research participants who can understand the child's inability to participate in another clinical trial during the time they are participating in the study;
- Legal guardian with intellectual capacity to fill out the signs of signs and symptoms at home.
Exclusion Criteria:
- Previous vaccination against measles and rubella;
- Personal history of measles or rubella;
- Personal history of anaphylactic shock, asthma, urticaria or other hypersensitivity reaction to previous vaccinations, or who are allergic or hypersensitive to vaccine components of the study;
- Use of antiallergic injections with antigens within 14 days or less prior to vaccination;
- Use of immunoglobulin in the last 12 months prior to vaccination;
- Use of blood products in the last 12 months prior to vaccination;
- Use of any type of vaccine less than 30 days prior to study vaccination;
- Use of injectable vaccines less than 42 days after study vaccination;
- Chronic use of any medications (except homeopathic medicines and trivial medication such as saline and vitamins);
- Previous use of immunosuppressive or cytotoxic medication;
- Use of systemic therapy with high doses of steroids;
- Use of any type of medication in a clinical trial within 12 months prior to vaccination;
- Personal history of clinically significant neurological, cardiovascular, respiratory, hepatic, renal, haematological, rheumatologic or autoimmune diseases;
- Personal history of coagulopathies diagnosed by a physician or report of capillary fragility;
- Personal history of seizures;
- Personal history of an active (eg any cancer) or treated malignant disease that may recur during the study;
- Personal history of sickle cell anemia;
- Asplenia (absence of spleen or removal of the spleen);
- HIV positive or history of any immunosuppressive disease;
- Presence of any disorder which, in the opinion of the principal investigator, may interfere with the evaluation of the study objectives;
- Legal guardian with limited capacity for adherence to the study, according to the researcher's evaluation;
- Impossibility of blood collection for pre-vaccine evaluation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Measles and Rubella vaccine
Biological/Vaccine: Administration of the experimental vaccine (Measles and Rubella).
|
Administration of the experimental vaccine (MR).
|
Active Comparator: Measles, Mumps and Rubella vaccine
Biological/Vaccine: Administration of the comparator vaccine (Measles, Mumps and Rubella).
|
Administration of the comparator vaccine (MMR).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity analysis of the study vaccine
Time Frame: 42 days after the 1st dose of MR or MMR
|
To evaluate imune response between post and pre-vaccination antibodies.
|
42 days after the 1st dose of MR or MMR
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reatogenicity analysis of the study vaccine
Time Frame: 30 days after the 1st dose of MR or MMR
|
To assess the occurrence of serious adverse events among individuals who received MR and MMR vaccines.
|
30 days after the 1st dose of MR or MMR
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kleber G Luz, PhD, Centro de Estudos e Pesquisas em Moléstias Infecciosas Ltda
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 20, 2018
Primary Completion (Actual)
August 12, 2020
Study Completion (Actual)
August 12, 2020
Study Registration Dates
First Submitted
May 9, 2017
First Submitted That Met QC Criteria
May 9, 2017
First Posted (Actual)
May 11, 2017
Study Record Updates
Last Update Posted (Actual)
August 13, 2020
Last Update Submitted That Met QC Criteria
August 12, 2020
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASCLIN 002/2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Measles
-
Bandim Health ProjectHeidelberg University; Centre de Recherche en Sante de Nouna, Burkina Faso; Navrongo... and other collaboratorsUnknownMeasles VaccineBurkina Faso
-
Bandim Health ProjectUnknown
-
Postgraduate Institute of Medical Education and...Unknown
-
Bandim Health ProjectHeidelberg University; Centre de Recherche en Sante de Nouna, Burkina Faso; Navrongo... and other collaboratorsUnknown
-
Serum Institute of India Pvt. Ltd.Centers for Disease Control and Prevention; University of Colorado, BoulderCompletedProphylaxis for the Measles InfectionIndia
-
Bandim Health ProjectEnrolling by invitationMortality | Measles Vaccine | Hospital Admission | Non-specific (Heterologous) Effects of VaccinesGuinea-Bissau
-
GlaxoSmithKlineCompletedMeasles; Mumps; Rubella | Measles-Mumps-Rubella VaccineUnited States, Finland, Taiwan, Estonia, Puerto Rico
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Not yet recruiting
Clinical Trials on Measles and Rubella vaccine
-
Sichuan Center for Disease Control and PreventionChina National Biotec Group Company LimitedUnknown
-
PT Bio FarmaCompletedSafety Issues | ImmunogenicityIndonesia
-
Laure Pittet, MD-PhDRecruitingInfections | Respiratory Tract Infections | Allergy | EczemaSwitzerland
-
PATHCompletedMeasles Antibody Seroconversion | Rubella Antibody Seroconversion | Rotavirus Geometric Mean Titer (GMT) | Rotavirus Immunoglobulin A (IgA) SeropositivityBangladesh
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | VaricellaBelgium, Germany, Netherlands
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | VaricellaGermany
-
Merck Sharp & Dohme LLCCompleted
-
Assistance Publique - Hôpitaux de ParisService de Bactériologie-Virologie-Hygiène, CHU Limoge; GO-CIC network (Réseau... and other collaboratorsCompleted
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | VaricellaFinland, Germany, Poland, Greece